# Amod A. Sarnaik

Source: https://onco.cc/people/amod-sarnaik/  
OnCo record `amod-sarnaik` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.

## Summary

Amod A. Sarnaik is a Surgical Oncologist in Cutaneous Oncology and a Senior Member at Moffitt Cancer Center, specialising in melanoma surgery and cellular immunotherapy. He is known as principal investigator of C-144-01, the pivotal trial of lifileucel that produced the first approved tumour-infiltrating lymphocyte therapy, with accelerated approval in advanced melanoma in 2024. His selected paper reports lifileucel, a tumour-infiltrating lymphocyte therapy, in metastatic melanoma. He continues to combine melanoma surgery with the development of TIL therapy at Moffitt.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Surgical Oncologist, Cutaneous Oncology; Senior Member
- Specialisms: Melanoma surgery; TIL therapy; Cellular immunotherapy

## Sources

- Moffitt profile: https://www.moffitt.org/providers/amod-sarnaik/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sarnaik%20AA%5BAuthor%5D

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)
- drugs: [Lifileucel](https://onco.cc/drugs/lifileucel/)
- institutions: [Moffitt Cancer Center](https://onco.cc/institutions/moffitt/)
- trials: [C-144-01](https://onco.cc/trials/c-144-01/)
- key papers: [C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed](https://onco.cc/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/)

---
JSON: https://onco.cc/api/v1/entities/amod-sarnaik.json